Abstract
Introduction: Induction with single dose therapy is rarely practiced in renal transplantation. Hence, we did this prospective study to see the influence of single dose induction therapy on graft function. Methods: Our study cohort comprised 358 patients (253 Males, 105 females) with a mean age of 43.42±13.22. Patients were divided into 4 groups based on the choice of induction therapy used (Basiliximab, Daclizumab, Thymoglobulin or no induction). Details such as age, sex, modality of dialysis and related details prior to transplantation, induction and immunosuppressive regimen, rate of rejection, diabetic status, previous transfusions, previous pregnancies, biopsy results and mortality were collected. Analysis was done using PASW Statistics 18 with chisquare test and one way Anova with post-hoc Tukey. The PRA values in thymoglobin was 26.17% ± 8.63% (Range:12.5% to 45.5%). The cost of the drugs is as follows - Basiliximab USD 1122, Thymoglobulin USD 551 and Daclizumab USD 800. Results: Of the 358 patients, single dose-induction was initiated on 310 patients; 125 with Basiliximab, 143 with Daclizumab (2 doses) and 42 patients with Thymoglobulin. Overall, 29.9% of patients were diabetic, however this was not significantly different across the groups (p=0.25). The transfusion rate was 53.8% in patients on thymoglobulin induction while the overall rate of transfusion was only 21.1% (p < 0.001). A positive biopsy report was seen in 24.5% of all patients (20.8% no induction; 27.2% Basiliximab, 23.8% Daclizumab, 23.1% Thymoglobulin) (p=0.82). Death-censored graft survival showed a lower incidence of graft survival with no induction (87.1%) (p=0.54).[Table 1 - Demographic and renal parameters]Figure: [Death-censored graft survival]Conclusion: Our study shows that single dose induction with thymoglobulin is the most cost effective modality in preventing rejection in patients with high PRA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.